Rating Change
BTIG reiterated its Buy rating on Lucid Diagnostics Inc. Common Stock (NASDAQ:LUCD) on August 17, 2026.
reiterateNASDAQ:LUCD
BTIG Reiterates Buy Rating on Lucid Diagnostics Inc. Common Stock (LUCD)
BTIG reiterated its Buy rating on Lucid Diagnostics Inc. Common Stock (NASDAQ:LUCD) on August 17, 2026.
At publication ·
What changed
Lucid Diagnostics Inc. Common Stock (NASDAQ:LUCD) · reiterate
- Firm
- BTIG
- Rating
- Buy to Buy
- Price at event
- $0.98
- Market capitalization
- $117.0M
At a glance
Key takeaways
- BTIG reiterated its Buy rating on Lucid Diagnostics (LUCD) on August 17, 2026, with the stock trading at $0.98 and a market capitalization of $117.0 million.
Market Context
Lucid Diagnostics Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $0.98 with a market capitalization of $117.0M. The stock has declined 6.0% over the past 52 weeks.
Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Lucid Diagnostics Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Lucid Diagnostics Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 17, 2026 | BTIG | Buy | N/A |
| Jun 08, 2026 | Ascendiant Capital | Buy | N/A |
| May 15, 2026 | BTIG | Buy | N/A |
| May 15, 2026 | Maxim Group | Buy | N/A |
| Apr 09, 2026 | Ascendiant Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View LUCD Stock Page
Frequently Asked Questions
What does the Buy rating mean for LUCD?
A rating of Buy from BTIG reflects the analyst's outlook on Lucid Diagnostics Inc. Common Stock (NASDAQ:LUCD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LUCD forecast page.